ReviewCurrent gene therapy2009
Electroporation advances in large animals.
Review in Current gene therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 36 citations in OpenAlex.
- Current and future treatments for sickle cell disease: From hematopoietic stem cell transplantation to in vivo gene therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2020Review
- Investigating the Impact of Delivery System Design on the Efficacy of Self-Amplifying RNA Vaccines.Vaccines · 2020Article
- Systematic optimization of square-wave electroporation conditions for bovine primary fibroblasts.BMC molecular and cell biology · 2020Article
- Electrotransfection and lipofection show comparable efficiency for in vitro gene delivery of primary human myoblasts.The Journal of membrane biology · 2015Article
- Plasmid IL-12 electroporation in melanoma.Human vaccines & immunotherapeutics · 2012Review
- A DNA vaccine for venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates.Clinical and vaccine immunology : CVI · 2011Article
- Pre-clinical toxicity assessment of tumor-targeted interleukin-12 low-intensity electrogenetherapy.Cancer gene therapy · 2011Article
- Numerical optimization of gene electrotransfer into muscle tissue.Biomedical engineering online · 2010Article
- Bleomycin/interleukin-12 electrochemogenetherapy for treating naturally occurring spontaneous neoplasms in dogs.Cancer gene therapy · 2010Article
- Bleomycin/interleukin-12 electrochemogene therapy for treating naturally occurring spontaneous neoplasms in dogs.Cancer gene therapy · 2010Article
- Optimization of DNA delivery by three classes of hybrid nanoparticle/DNA complexes.Journal of nanobiotechnology · 2010Article
- Bioelectric controls of cell proliferation: ion channels, membrane voltage and the cell cycle.Cell cycle (Georgetown, Tex.) · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
In vivo electroporation-mediated gene therapy in large animals is gaining ground as one of the most important means for non-viral gene therapy. This review focuses on the novel aspects of reversible electroporation as applied to large animals, improvement of electroporation delivery technique, and development of electroporation-based vaccines. In regard to large animals, we have summarized the initial use of electroporation-mediated antineoplastic gene therapy in humans, vaccination in monkeys, reversing and preventing cachexia in dogs, and increases growth rate and piglet survival in pigs. Novel techniques incorporating electroporation, including ex vivo manipulations, electron avalanche transfection, and electrosonoporation illustrate evolving modifications. Specific alterations of electroporation parameters and DNA formulations along with ideas of enhancing gene transfection efficiency are provided in addition to a discussion of some of the current limitations of electroporation-mediated gene therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.